European Commission Approves Ritlecitinib for Severe AA
This makes ritlecitinib the first medicine authorized by the EC to treat individuals with severe alopecia areata as young as 12 years of age.
Stay updated with breaking news from Nt Ears. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This makes ritlecitinib the first medicine authorized by the EC to treat individuals with severe alopecia areata as young as 12 years of age.
The latest e-nose features an energy-efficient design that researchers hope will be applicable in food and healthcare settings.
Recommendations from a multidisciplinary team of experts address safety, proper training, and implementation in use of thermal and other types of benign thyroid ablation.
Dupilumab demonstrated real-world efficacy in patients with severe, treatment-refractory fibrostenotic eosinophilic esophagitis, most of whom would not have qualified for prior clinical trials.
Symptoms like anosmia and parosmia lingered for years. Both conditions caused a deep and life-altering depression that pushed Henderson to the brink of hopelessness.